辅酶Q10联合盐酸曲美他嗪辅助治疗冠心病心力衰竭的疗效及对血清NT-proBNP及CPP水平的影响分析  

Therapeutic effects of coenzyme Q10 combined with trimetazidine hydrochloride as an adjuvant treatment of coronary heart disease and heart failure, and its influence on levels of serum NT-proBNP and CPP

作　　者：刘洋[1] LIU Yang(Department of Internal Medicine,Dadong Hospital Affiliated to the First Affiliated Hospital of China Medical University,Shenyang 110000,China)

机构地区：[1]中国医科大学附属第一医院大东医院内科,110000

出　　处：《中国实用医药》2021年第35期15-17,共3页China Practical Medicine

摘　　要：目的研究辅酶Q10联合盐酸曲美他嗪辅助治疗冠心病心力衰竭患者的疗效及对血清N端脑钠肽前体(NT-proBNP)及和肽素(CPP)水平的影响。方法100例冠心病心力衰竭患者,按照随机数字表法分为对照组和实验组,各50例。对照组给予盐酸曲美他嗪进行治疗,实验组给予辅酶Q10联合盐酸曲美他嗪治疗。对比两组治疗效果、心脏功能及血清N末端脑钠肽前体(NT-proBNP)、CPP、微管连接蛋白(Nexilin)、心型脂肪酸结合蛋白(H-FABP)水平。结果治疗前,两组患者血清NT-proBNP、CPP、Nexilin、H-FABP水平对比,差异无统计学意义(P>0.05);治疗后,实验组患者NTproBNP、CPP、Nexilin、H-FABP水平均明显低于对照组,差异有统计学意义(P<0.05)。实验组患者治疗总有效率94.00%明显高于对照组的76.00%,差异有统计学意义(P<0.05)。治疗前,两组患者左室收缩末期容积指数(LVESVI)、左室射血分数(LVEF)、左室舒张末期容积指数(LVEDVI)、每搏输出量(SV)对比差异无统计学意义(P>0.05);治疗后,实验组患者LVESVI(39.13±4.41)ml/m^(2)、LVEF(43.71±6.44)%、LVEDVI(64.12±5.20)ml/m^(2)、SV(57.24±7.43)ml均明显优于对照组的(41.48±4.02)ml/m^(2)、(39.56±5.11)%、(67.11±5.15)ml/m^(2)、(48.69±6.85)ml,差异有统计学意义(P<0.05)。结论辅酶Q10联合盐酸曲美他嗪辅助治疗冠心病心力衰竭患者的疗效显著,可有改善血清NT-proBNP、CPP、Nexilin、H-FABP水平,提高心脏功能,临床可积极推广。Objective To study the therapeutic effect of coenzyme Q10 combined with trimetazidine hydrochloride as an adjuvant treatment of patients with coronary heart disease and heart failure,and its influence on levels of serum N-terminal pro-brain natriuretic peptide(NT-proBNP)and copeptin(CPP).Methods 100 patients with coronary heart disease and heart failure were randomly divided into control group and experimental group,with 50 cases in each group.Patients in the control group were administered with trimetazidine hydrochloride,while patients in the experimental group were administered with coenzyme Q10 combined with trimetazidine hydrochloride.Clinical therapeutic effect,cardiac function and levels of serum N-terminal pro-brain natriuretic peptide(NT proBNP),CPP,Nexilin and heart fatty acid binding protein(H-FABP)were compared between the two groups.Results Before the treatment,differences in the levels of serum NT-proBNP,CPP,Nexilin and H-FABP between the two groups were not statistically significant(P>0.05).After the treatment,the levels of serum NT-proBNP,CPP,Nexilin and H-FABP of the experimental group were significantly lower than those of the control group,and the differences were statistically significant(P<0.05).The overall therapeutic effective rate of the experimental group was 94.00%,which was significantly higher than 76.00%of the control group,and the difference was statistically significant(P<0.05).Before the treatment,differences in left ventricular end systolic volume index(LVESV),left ventricular ejection fraction(LVEF),left ventricular end diastolic volume index(LVEDVI)and stroke volume(SV)between the two groups were not statistically significant(P>0.05).After the treatment,the experimental group had LVESV of(39.13±4.41)ml/m^(2),LVEF of(43.71±6.44)%,LVEDVI of(64.12±5.20)ml/m^(2) and SV of(57.24±7.43)ml,which were significantly better than (41.48±4.02) ml/m^(2), (39.56±5.11)%, (67.11±5.15) ml/m^(2) and (48.69±6.85) ml of the control group, respectively, and the differences were statistically

关 键 词：辅酶Q10 盐酸曲美他嗪 冠心病 心力衰竭 血清N末端脑钠肽前体 和肽素 

分 类 号：R541.6[医药卫生—心血管疾病] R541.4[医药卫生—内科学]